DSIP and the FDA: where emideltide stands in 2026

Approved, compounded and 'research use'

No company has an FDA-approved DSIP product. That means it has never passed the clinical trials and FDA review required to show it is safe and effective for a specific condition.

A licensed pharmacy can sometimes prepare a compounded version for an individual patient with a prescription, but only if the ingredient qualifies under federal compounding rules. The FDA states that compounded drugs are not FDA-approved and that it does not verify their safety, effectiveness or quality. Products sold online as 'research peptides' are neither approved nor prescriptions and should not be used in people.

How DSIP got here

• Earlier: The FDA placed emideltide among bulk substances that may present significant safety risks, citing possible immune reactions, peptide-related impurities, difficulties characterizing the ingredient, and no safety data for the proposed route.
• April 2026: The FDA's safety-risk page moved emideltide to a section of substances 'nominated but withdrawn' by their nominators. This was not a finding of safety.
• July 24, 2026: The Pharmacy Compounding Advisory Committee reviewed emideltide for opioid withdrawal, chronic insomnia and narcolepsy and voted 6 to 7, with one abstention, against recommending it for the 503A bulks list.
• October 2026: No final FDA decision has been published.

Why FDA staff and the committee were skeptical

According to RAPS coverage of the meeting, FDA staff said DSIP was not adequately characterized and could contain impurities from the way peptides are made, such as incomplete or truncated chains. An FDA reviewer described a lack of safety and efficacy data for the proposed uses, and staff noted that approved treatments already exist for insomnia, narcolepsy and opioid withdrawal.

Committee members who voted no pointed to those safety and efficacy concerns, the low quality of the efficacy evidence and the availability of approved drugs. Others supported access when a valid prescription is involved, which is why the vote was so close.

What the vote does and does not mean

The FDA states that advisory committees make non-binding recommendations. The agency can follow or depart from a vote, and any decision to add a substance to the bulks list would require rulemaking with public comment.

In practical terms, a negative vote makes it less likely that DSIP will be added to the list soon. Under section 503A, pharmacies generally may compound only with bulk ingredients that have a USP monograph, are part of an FDA-approved drug, or appear on the bulks list, and DSIP currently meets none of these. Whether any pharmacy can dispense it lawfully depends on current federal and state rules, which can change.

Compared with other peptides reviewed that week

The same two-day meeting reviewed seven peptides. RAPS reported that the committee recommended six of them, including BPC-157, KPV, TB-500, MOTS-c, epitalon and Semax, and rejected only emideltide. None of the seven is FDA-approved, and none of the favorable votes was final FDA action. The contrast is still meaningful: DSIP did not persuade even a committee inclined toward broader access.

How to protect yourself

Peptide marketing moves faster than regulation, and DSIP is often sold with confident claims about deep sleep and stress relief. A few checks help you separate a legitimate prescription from a risky purchase.

• A licensed clinician should review your sleep history, medicines and health conditions before any prescription
• The product should come from a named, state-licensed U.S. pharmacy, with a patient-specific label
• Ask on what basis the pharmacy can compound the ingredient under current rules
• Avoid vials labeled 'for research use only' or 'not for human consumption'
• Be wary of any seller that publishes dosing protocols or promises results
• Report side effects to your clinician and to the FDA's MedWatch program

What this means for your sleep plan

Insomnia has effective, well-studied treatments. The National Heart, Lung, and Blood Institute notes that cognitive behavioral therapy for insomnia (CBT-I) is usually recommended first for long-term insomnia, and several FDA-approved medicines exist. Sleep apnea, menopause symptoms, alcohol, pain and medications are common, treatable causes of poor sleep in midlife.

HealifyMD starts with a sleep-focused assessment. DSIP is considered only when a clinician judges it reasonable after that review and a licensed U.S. pharmacy confirms it can lawfully dispense it. It is a compounded preparation, not FDA-approved and not reviewed by the FDA for safety, effectiveness or quality. The listed price starts at $200/month, or $350 for two months ($175/month), with no membership fee, confirmed at the eligibility review.